Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any isolated microphthalmia in which the cause of the disease is a mutation in the ALDH1A3 gene.
Features include common findings: Optic nerve hypoplasia, Retinal detachment, Retinal coloboma, and Anophthalmia and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 4 | Optic nerve hypoplasia, Retinal detachment, Retinal coloboma |
ALDH1A3 encodes aldehyde dehydrogenase 1 family member A3 (512 aa). Catalyzes the NAD-dependent oxidation of aldehyde substrates, such as all-trans-retinal and all-trans-13,14-dihydroretinal, to their corresponding carboxylic acids, all-trans-retinoate and all-trans-13,14-dihydroretinoate, respectively. Highest expression in Prostate (63.7 TPM) and Minor Salivary Gland (61.3 TPM).
Isolated microphthalmia 8 is associated with mutations in the ALDH1A3 gene on chromosome 15.
The ALDH1A3 protein participates in ALDH1A3 tetramer, Mammary stem cell produces myoepithelial/basal progenitor, and Mammary hormone receptor negative luminal progenitor cell produces alveolar progenitor cell pathways.
ALDH1A3 is classified as a druggable target (Druggable Genome and Enzyme categories) with score 2.5.
Genetic testing for ALDH1A3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 9 common features.
No clinical trials have been registered for isolated microphthalmia 8.
9 publications have been identified in PubMed for isolated microphthalmia 8. Research spans Case Report / Case Series (33%), Basic Science / Preclinical (22%), and Gene Therapy / Novel Therapeutics (22%).
Xie W (2025). [PMID: 40817209](https://pubmed.ncbi.nlm.nih.gov/40817209/). *BMC pregnancy and childbirth*. [Case Report / Case Series]
Arcot Sadagopan K (2025). [PMID: 40083070](https://pubmed.ncbi.nlm.nih.gov/40083070/). *Ophthalmic genetics*. [Case Report / Case Series]
Jiménez Cruz J (2025). [PMID: 40040326](https://pubmed.ncbi.nlm.nih.gov/40040326/). *Acta obstetricia et gynecologica Scandinavica*. [Basic Science / Preclinical]
Ni J (2025). [PMID: 40366612](https://pubmed.ncbi.nlm.nih.gov/40366612/). *Molecular and cellular biochemistry*. [Gene Therapy / Novel Therapeutics]
Choi BM (2025). [PMID: 39809510](https://pubmed.ncbi.nlm.nih.gov/39809510/). *Journal of microbiology and biotechnology*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 2:38 PM UTC
Online Mendelian Inheritance in Man
Merepa SS (2025). [PMID: 40301690](https://pubmed.ncbi.nlm.nih.gov/40301690/). *European journal of human genetics : EJHG*. [Epidemiology / Natural History]
Amaral RAS (2024). [PMID: 38557281](https://pubmed.ncbi.nlm.nih.gov/38557281/). *Ophthalmic genetics*. [Case Report / Case Series]
Li D (2024). [PMID: 39007834](https://pubmed.ncbi.nlm.nih.gov/39007834/). *Translational vision science & technology*. [Gene Therapy / Novel Therapeutics]
Mahmoud A (2024). [PMID: 38350011](https://pubmed.ncbi.nlm.nih.gov/38350011/). *Ocular immunology and inflammation*. [Review / Meta-Analysis]